Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Immunoassay Developed for Histoplasmosis Diagnosis

By LabMedica International staff writers
Posted on 27 Jan 2011
An immunoassay, using purified deglycosylated antigen, has been developed to diagnose different manifestations of the fungal disease histoplasmosis. More...


The enzyme-linked immunosorbent assay (ELISA) detects antibodies to Histoplasma capsulatum, the causative agent of histoplasmosis, using metaperiodate treated purified histoplasmin (ptHMIN), the specific antigen of this fungus.

To evaluate the ELISA test clinical serum samples were selected randomly from the Immunodiagnostic Section Serum Bank, Laboratory of Mycology, Institute of Clinical Research Evandro Chagas, (Fiocruz; Rio de Janeiro, Brazil). Forty-four sera samples were tested from homologous histoplasmosis and 35 sera samples from other cases of mycoses. These included seven with paraccocidioidomycosis; eight for each of the following: aspergillosis sporotrichosis, and cryptococcosis cases, and four from coccidioidomycosis patients. Additionally, 36 negative control sera from healthy donors were collected and tested.

The results of the assay showed that the optical densities (ODs) were significantly higher in sera from 44 patients with histoplasmosis than in heterologous-infected samples evaluated. Differences in the means and comparisons of parameters indicate that the test effectively discriminates between negative and positive samples. The distribution of OD values varied in the clinical groups, but no statistical differences were found between them. The OD values are an indication of antibody levels in the patients' sera.

The overall test specificity was 96%, with sensitivities of 100% in acute disease, 90% in chronic disease, 86% in disseminated disease co-infected with Human Immunodeficiency Virus (HIV), 89% in disseminated infection in individuals without HIV infection, and 100% in mediastinal histoplasmosis. The authors of the study concluded that the high specificities, sensitivities, and simplicity of the ELISA support further development of a deglycosylated HMIN ELISA for clinical use and for monitoring the humoral immune response during therapy in patients with chronic and disseminated histoplasmosis.

Histoplasmosis is a disease caused when airborne spores of the fungus H. capsulatum are inhaled into the lungs, the primary infection site. This microscopic fungus, which is found throughout the world in river valleys and soil where bird or bat droppings accumulate, is released into the air when soil is disturbed by plowing fields, sweeping chicken coops, or digging holes. The clinical disease generally ranges from mild influenza-like illnesses to progressive, disseminated disease, which manifests mostly in immunocompromised individuals. The study was published on line on January 4, 2010, in the open access journal Microbiology Research.

Related Links:

Institute of Clinical Research Evandro Chagas





Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.